A pilot study of the efficacy and safety of sivelestat sodium hydrate to prevent acute exacerbation after thoracoscopic lung biopsy in patients suspected of interstitial lung diseases whose bronchoalveolar fluid showed neutrophils.
Phase 2
- Conditions
- interstitial lung disease
- Registration Number
- JPRN-UMIN000006148
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients complicated by four or more organ failures including lungs 2) Patients in pregnancy, lactation, or possible pregnancy 3) Patients to whom the physician in-charge judged not suitable for the study 4) Patients using steroid 5) Patients who against or depart gravely from the protocol in dose, dosing schedule, and/or the combination of therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of acute exacerbation for 2 weeks after VATS
- Secondary Outcome Measures
Name Time Method